摘要
母婴传播是乙型肝炎病毒(hepatitis B virus,HBV)传播的主要途径之一,也是HBV感染后慢性化的主要原因,因此,阻断HBV母婴传播对于降低慢性乙型肝炎发病率尤为重要。目前,用于HBV母婴阻断的核苷(酸)类似物(Nas)有拉米夫定、替比夫定、富马酸替诺福韦二吡呋酯,富马酸丙酚替诺福韦亦开始用于妊娠期慢性乙型肝炎患者。该文总结上述药物在HBV母婴阻断中的疗效、安全性以及抗病毒治疗指征和停药时间,为母婴阻断Nas的选择及合理应用提供参考。
Mother-to-child transmission of hepatitis B virus(HBV)is one of the main ways of transmission and the main cause of chronic hepatitis B after infection.Therefore,preventing mother-to-child transmission of HBV is particularly important in reducing the incidence of chronic hepatitis B.Currently,nucleoside(acid)analoids(Nas)used for mother-to-child blocking of HBV include lamivudine(LAM),tibivudine(LdT)and tenofovir fumarate(TDF).Propofol tenofovir fumarate(TAF)has also been used in pregnant chronic hepatitis B patients.This paper summarizes the efficacy,safety and antiviral treatment indications and termination time of the above-mentioned drugs in mother-to-child preventing to provide suggestions for the selection and rational application of mother-to-child preventing Nas.
作者
郑洲松
黄燕
黄泽炳
ZHENG Zhou-song;HUANG Yan;HUANG Ze-bing(Zhuzhou Hospital Affiliated to Xiangya School of Medicine,Central South University,Zhuzhou Hunan 412007,China;Dept of Infectious Diseases,Xiangya Hospital,Central South University,Key Laboratory of Viral Hepatitis of Hunan Province,National Clinical Research Center for Geriatrics,Changsha 410008,China)
出处
《中国药理学通报》
CAS
CSCD
北大核心
2023年第12期2221-2224,共4页
Chinese Pharmacological Bulletin
基金
国家科技重大专项(No 2018ZX10723203-004-003)。
关键词
慢性乙型肝炎
母婴阻断
核苷(酸)类似物
疗效
安全性
治疗进展
chronic hepatitis B
prevention of mother-to-child transmission
nucleoside analogues
efficacy
safety
treatment progress
